Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Fosaprepitant dimeglumine/palonosetron hydrochloride - Beihai Biotech

Next Previous
Drug Profile

Fosaprepitant dimeglumine/palonosetron hydrochloride - Beihai Biotech

Alternative Names: BH-006; Palonosetron hydrochloride/fosaprepitant dimeglumine - Beihai Biotech

Latest Information Update: 29 Jul 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beihai Biotech
  • Class Antiemetics; Fluorinated hydrocarbons; Isoquinolines; Morpholines; Phosphinic acids; Phosphonic acids; Quinuclidines; Small molecules; Triazoles
  • Mechanism of Action Neurokinin 1 receptor antagonists; Serotonin 3 receptor antagonists; Substance P inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Chemotherapy-induced nausea and vomiting

Most Recent Events

  • 17 Jun 2022 Fosaprepitant dimeglumine/palonosetron hydrochloride - Beihai Biotech is available for licensing as of 16 Jun 2022. http://www.bayhibiotech.com/page115
  • 06 Apr 2022 The Center for Drug Evaluation (CDE) of the State Drug Administration accepts clinical trial application of BH 006 in Chemotherapy-induced nausea and vomiting
  • 06 Apr 2022 Beihai Biotech plans clinical trial in Chemotherapy-induced nausea and vomiting in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top